Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PHASE-II STUDY OF AMONAFIDE IN PATIENTS WITH RECURRENT GLIOMA
Autore:
LEVITT R; BUCKNER JC; CASCINO TL; BURCH PA; MORTON RF; WESTBERG MW; GOLDBERG RM; GALLAGHER JG; OFALLON JR; SCHEITHAUER BW;
Indirizzi:
MAYO CLIN,200 1ST ST SW ROCHESTER MN 55905 ST LUKES HOSP,CCOP FARGO ND 00000 MAYO CLIN & MAYO FDN ROCHESTER MN 55905 IOWA ONCOL RES ASSOC,CCOP DES MOINES IA 50314 GEISINGER CLIN ONCOL PROGRAM DANVILLE PA 17822
Titolo Testata:
Journal of neuro-oncology
fascicolo: 1, volume: 23, anno: 1995,
pagine: 87 - 93
SICI:
0167-594X(1995)23:1<87:PSOAIP>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
SOUTHWEST-ONCOLOGY-GROUP; CELL LUNG-CANCER; TRIAL;
Keywords:
BRAIN NEOPLASM; AMONAFIDE; CHEMOTHERAPY; GLIOMA; ASTROCYTOMA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
19
Recensione:
Indirizzi per estratti:
Citazione:
R. Levitt et al., "PHASE-II STUDY OF AMONAFIDE IN PATIENTS WITH RECURRENT GLIOMA", Journal of neuro-oncology, 23(1), 1995, pp. 87-93

Abstract

Amonafide, a novel imide derivative with broad preclinical antitumor activity, achieves significant cerebrospinal fluid levels in animal models. In order to test its antitumor activity in patients with recurrent diffuse infiltrative glioma of the astrocytic and oligodendroglial type, we performed a phase II clinical trial. Of the 22 eligible and evaluable patients treated, 2 (9%) experienced tumor regression lastingmore than one year. No other patients experienced tumor regression; one remained stable more than six months. Toxicities consisted primarily of myelosuppression, vomiting, and venous irritation at the infusionsite. We conclude that amonafide has minimal activity in recurrent glioma patients. Further investigations are not warranted in this study population.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 09:17:33